FFR technology poised for growth as quality, cost benefits mount

01/14/2013 | Bloomberg

Fractional flow reserve tests, which assess arterial pressure as a way to evaluate the effects of blockage, have offered physicians a more precise way to determine which patients are good candidates for stenting. That helps ensure they get optimal treatment when they need it, according to SCAI secretary Dr. James Blankenship, keeping quality high and costs relatively low. The market for FFR tests was forecast to reach $200 million in 2012 and could grow rapidly if the technology is found to have similar success in arteries in other parts of the body.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD